Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

ClinicalTrials.gov ID: NCT02106832

Public ClinicalTrials.gov record NCT02106832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

Study identification

NCT ID: NCT02106832
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 521 participants

Conditions and interventions

Conditions

Bronchiectasis

Interventions

Ciprofloxacin (BAYQ3939) dry powder for inhalation Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2014 (Actual)
Primary completion: Sep 13, 2016 (Actual)
Completion: Oct 19, 2016 (Actual)
Last update posted: Oct 2, 2017

2014 – 2016

United States locations

U.S. sites: 22
U.S. states: 13
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Peoria	Arizona	85381	—
Not listed	Fountain Valley	California	90708	—
Not listed	La Jolla	California	92037	—
Not listed	Long Beach	California	90813	—
Not listed	Newport Beach	California	92663	—
Not listed	San Diego	California	92120	—
Not listed	Kissimmee	Florida	34741	—
Not listed	Miami	Florida	33126	—
Not listed	Sarasota	Florida	34239	—
Not listed	Tampa	Florida	33613	—
Not listed	Decatur	Georgia	30033	—
Not listed	Skokie	Illinois	60076	—
Not listed	Olathe	Kansas	66061	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Brooklyn	New York	11229	—
Not listed	Mineola	New York	11501	—
Not listed	Asheville	North Carolina	28801	—
Not listed	Portland	Oregon	97239	—
Not listed	Doylestown	Pennsylvania	18901	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Edinburg	Texas	78539	—
Not listed	Tyler	Texas	75708-3154	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02106832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 2, 2017 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02106832 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →